CPL 976 MMAE
Alternative Names: CPL-976-MMAE; CPL976 H-MMAELatest Information Update: 17 Jul 2026
At a glance
- Originator Celon Pharma
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; Axl receptor tyrosine kinase inhibitors; B7-H1 antigen inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Apr 2026 Pharmacokinetics and pharmacodynamics data from a preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 11 Oct 2023 Preclinical trials in Solid tumours in Poland (Parenteral)
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023)